Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Germany
/
Pharmaceuticals & Biotech
Create a narrative
Novo Nordisk
DB:NOVA Community
Create a narrative
Novo Nordisk
Undervalued
Overvalued
Novo Nordisk
AN
AndyB72
Community Contributor
Q4 2024 Italian language
Ecco cosa dicono gli utili di Novo Nordisk del Q4 2024 Nonostante le azioni si trovino ai minimi degli ultimi 15 mesi e il sentiment generale sia un po' ribassista, i dati del Q4 offrono spunti interessanti. Il colosso farmaceutico europeo ha registrato un incremento del 30,1% nelle vendite , raggiungendo 11,48 miliardi EUR, superando così le attese.
View narrative
€81.64
FV
0.2% overvalued
intrinsic discount
3.00%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
4 days ago
author updated this narrative
Your Valuation for
NOVA
Novo Nordisk
Your Fair Value
€
Current Price
€81.80
30.4% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
499b
2015
2018
2021
2024
2025
2027
2030
Revenue DKK 499.2b
Earnings DKK 173.6b
Advanced
Set as Fair Value